Tenofovir (Aggiornato al 07/07/2016)

A cura di Simona Lucchesi. UOSD Farmacologia Clinica. AOU “G. Martino” Messina

Principio attivo

Effetto

Atazanavir (1,2)

Diminuzione della concentrazione/esposizione di atazanavir e/o aumento della concentrazione di tenofovir

Darunavir (3)

Aumento dell’esposizione a tenofovir

Didanosina (4-12)

Aumento delle concentrazioni plasmatiche di didanosina e rischio di tossicità da didanosina (neuropatia, diarrea, pancreatite, acidosi lattica severa)

Lopinavir (13)

Aumento della biodisponibilità di tenofovir

Ritonavir (14)

Aumento della biodisponibilità di tenofovir

Tipranavir (15)

Diminuzione delle concentrazioni plasmatiche di tipranavir

Bibliografia

  1. Product Information: REYATAZ(R) oral capsules, atazanavir sulfate oral capsules. Bristol-Myers Squibb Company, Princeton, NJ, Feb, 2011.
  2. Product Information: VIREAD(R) oral tablets, tenofovir disoproxil fumarate oral tablets. Gilead Sciences, , Foster City, CA, Oct, 2010.
  3. Product Information: VIREAD(R) oral tablets, oral powder, tenofovir disoproxil fumarate oral tablets, oral powder. Gilead Sciences, Inc. (per FDA), Foster City, CA, Oct, 2013.
  4. Richard JN, et al. Pancreatitis with didanosine and tenofovir disoproxil fumarate (corrected). Clin Infect Dis 2003; 37: e57-62.
  5. Fulco P, Kirian M. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 2003; 27: 1325-1328.
  6. Guo Y, Fung HB. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 2004; 24: 1089-1094.
  7. Kearney BP, Damle B, Plummer A et al. Tenofovir DF (TDF) and didanosine EC (ddl EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002, p 186, 2002.
  8. Kirian MA, et al. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother 2004; 38: 1660-1663.
  9. Martinez E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364: 65-67.
  10. Murphy M, et al. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infec Dis 2003; 36: 1082-1085.
  11. Negredo E, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Aids 2004; 18: 459-463.
  12. S. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC, Oct 14, 2011. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf’utm_source=AAG&utm_medium=E-mail&utm_campaign=Adult%2BGuidelines.
  13. Product Information: VIREAD(R) Oral Tablet , tenofovir disoproxil fumarate oral tablet. Gilead Sciences, Inc, Foster City, CA, May, 2005
  14. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo, Department of Health and Human Services, Rockville, MD, Apr 06, 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
  15. Langmann P, et al. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring. Eur J Med Res 2008; 13: 469-471.

Link

Zidovudina, tenofovir e abacavir: quali effetti avversi?

Ultimo aggiornamento: 28 luglio 2016